Yagiz Anil Cicek (Rotello group): Small interfering RNA (siRNA) therapeutics offer a powerful approach for targeted gene silencing, providing solutions for diseases that are difficult to treat with conventional therapies. However, clinical translation is limiting by challenges such as instability, off-target effects, and inefficient intracellular delivery. My research focuses on developing engineered polymeric delivery vehicles for precise and effective siRNA treatments of cancer, acute respiratory distress syndrome (ARDS), and wound biofilm infections. These vehicles self-assemble with the siRNA to form polyplexes and are engineered to provide stability in biological environments, efficient cellular delivery, and high therapeutic efficacy. In our work, we demonstrated the effectiveness of these polyplexes in animal models of triple-negative breast cancer, ARDS, and wound biofilm infections. These polyplexes not only enhanced the stability and bioavailability of the siRNA but also minimized adverse effects commonly associated with conventional therapies. Our findings highlight the potential of engineered polymer-siRNA systems as a transformative platform to address different disease pathways, paving the way for more precise and efficient therapeutic solutions.